Todd Brown
Optometrist · Mesa, AZNPI 1720419534
Payments from drug & device makers
Across 96 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$357
- AbbVie$323
- Alcon$200
- Sun Pharmaceutical Industries Inc.$165
- Amgen$153
- Harrow Eye, LLC$148
- plus $711 from 15 others
What the payments were for
- Food & beverage$2,04099%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 19 | $357 |
| AbbVie(2 entities) | 17 | $323 |
| Alcon | 9 | $200 |
| Sun Pharmaceutical Industries Inc. | 7 | $165 |
| Amgen(2 entities) | 9 | $153 |
| Harrow Eye, LLC | 5 | $148 |
| Novartis | 7 | $133 |
| Kala Pharmaceuticals, Inc. | 6 | $112 |
| Glaukos Corporation | 1 | $105 |
| Coopervision Inc. | 1 | $62 |
| Dompe US, Inc. | 2 | $50 |
| Oyster Point Pharma, Inc. | 2 | $41 |
| Aerie Pharmaceuticals, Inc. | 2 | $35 |
| Thea Pharma Inc. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Shire North American Group Inc | 1 | $21 |
| ABB Con-cise Optical Group LLC | 1 | $21 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $20 |
| Sight Sciences, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDoseTR$105
How this compares
$2,057 in reported general payments places this provider in the 75th percentile of 1,134 optometrist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 105 | $143,425 |
| LumiganBimatoprost | 73 | $47,431 |
| XiidraLifitegrast | 35 | $38,775 |
| Cyclosporine | 26 | $22,354 |
| Prednisolone Acetate | 577 | $19,188 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $7,241 |
| Latanoprost | 525 | $6,350 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $5,934 |
| Travoprost | 11 | $2,638 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,538 |
| Dorzolamide Hcl | 97 | $1,964 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 127 | $1,513 |
| Timolol Maleate | 147 | $1,302 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 89 | $1,156 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $1,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $323 | $193,394191 claims |
| Bausch & Lomb Americas Inc.Xiidra | $357 | $38,77535 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $35 | $7,24116 claims |
| AlconSimbrinza | $200 | $5,93421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,134 optometrist providers in Arizona.
Other optometrist in Mesa
- Kerry PearsonMesa$10K
- Matthew PalmerMesa$8K
- Frank AkersMesa$7K
- Marc BloomensteinScottsdale$2.3M
- Stephanie WooLake Havasu City$540K
- Kevin HelmuthSacaton$281K
- Christina SorensonGlendale$181K
- Jashpal RajasansiGilbert$120K
- Michelle Marie MijaresFort Defiance$38K
- Jamie KuhnGlendale$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.